

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number  
**WO 2004/076403 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 303/40**,  
303/44, C07D 209/14, C07C 311/35

(21) International Application Number:  
PCT/US2004/005560

(22) International Filing Date: 23 February 2004 (23.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/449,554 24 February 2003 (24.02.2003) US

(71) Applicant (for all designated States except US): **TRANS-  
FORM PHARMACEUTICALS, INC.** [US/US]; 29  
Hartwell Avenue, Lexington, MA 02421 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MORISSETTE,  
Sherry, L.** [US/US]; 11 Brattle Drive, #10, Arlington, MA  
02474 (US). **ALMARSSON, Örn** [IS/US]; 22 Farmington  
Drive, Shrewsbury, MA 01545 (US). **READ, Michael**  
[US/US]; 40 Kings Way, #503B, Waltham, MA 02451  
(US).

(74) Agents: **EISENSCHENK, Frank, C.** et al.; Saliwanchik,  
Lloyd & Saliwanchik, A Professional Association, 2421  
NW 41st Street, Suite A-1, Gainesville, FL 32606-6669  
(US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SUMATRIPTAN CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS

(57) Abstract: The invention provides novel soluble sumatriptan crystalline forms that include polymorphs, salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these sumatriptan crystalline forms. Methods of using such compositions for the treatment or prevention of migraine headaches and related neurological disorders are also provided.



**WO 2004/076403 A1**

## SUMATRIPTAN CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS

## CROSS-REFERENCE TO RELATED APPLICATIONS

10           This application claims the benefit of U.S. application 60/449,554, filed February 24, 2003. This application is all hereby incorporated by reference in its entirety, including all figures, formulae, references and tables.

## FIELD OF INVENTION

15

          The invention provides novel soluble sumatriptan crystalline forms that include polymorphs, salts, co-crystals and related solvates useful as pharmaceuticals.

          The invention also provides pharmaceutical compositions comprising, and  
20       processes for making, novel sumatriptan crystalline forms. Methods of using such compositions for the treatment or prevention of migraine headaches and related neurological disorders are also provided. In preferred embodiments, the invention provides novel soluble multicomponent crystalline systems or polymorphs comprising: (a) an organic salt comprising the reaction product of sumatriptan and an  
25       organic or inorganic acid.

## BACKGROUND OF THE INVENTION

30           A working definition of migraine is a benign recurring headache and/or neurologic dysfunction, more common in women than men. Classic migraine (migraine with aura) refers to the syndrome of a severe, throbbing headache which often is preceded by sensory, motor or visual symptoms, referred to as an "aura." Common migraine (migraine without aura) denotes a headache without the aura.  
35       Common migraine is the most frequent headache type reported by patients.

          Migraine attacks may last from four to seventy-two hours and are exacerbated by movement. They are accompanied by nausea and or vomiting or sensitivity to light

5 and noise, or both. Usually, the pain is one-sided and pulsating. The typical sufferer retreats to a darkened bedroom for the duration of the attack, unless symptoms are relieved by early treatment. A minority (10%) of migraine sufferers experience an aura prior to the attack. The migraine aura most commonly consists of visual disturbances or partial loss of vision, but neurological signs such as paresthesias (e.g., a tingling  
10 sensation) can also occur.

The level of pain and disability associated with migraine can vary greatly. Some migraine sufferers can sleep off the attack with the aid of over-the-counter analgesics. Others may be completely disabled for 24 hours or longer, with severe  
15 head pain and nausea.


Many drugs are now available for prophylactic treatment of migraine. They must be taken daily. The major drugs for prophylaxis are propranolol, amitriptyline, valproate, verapamil, phenelzine, and methysergide. Use of methysergide carries with  
20 it the danger of retroperitoneal fibrosis. Aspirin-like drugs, including aspirin, naproxen, ibuprofen, mefenamic acid, flufenamic acid, and tolfenamic acid are in use as prophylactic agents. The high dosage of these compounds required for effectiveness is a drawback. It has been estimated that the probability of success with any one of the available prophylactic antimigraine drugs is about 60 to 75%  
25 (Harrison's Principles of Internal Medicine, eds. Isselbacher et al., McGraw-Hill, Inc., New York, 1994, p. 69). Accordingly, development or identification of drugs for prophylactic treatment of migraine is an area of continuing medical need.

It has been known for some time that sumatriptan, which causes constriction  
30 of cranial blood vessels, is an effective treatment for migraine (see, for example, Doenicke et al., Lancet, 1988, Vol. 1, 1309-11; and Feniuk & Humphrey, Drug Development Research, 1992, 26, 235-40). As such, it is the prototypical example of a class of compounds which have recently been classified (Hartig et al., TIPS, 1996, 17, 103-105) as 5-HT<sub>1B</sub>/5-HT<sub>1D</sub> receptor agonists. Activation of 5-HT<sub>1B</sub> and/or 5-HT<sub>1D</sub>  
35 receptors leads to (1) selective vasoconstriction of certain cranial extracerebral blood

5 vessel segments; (2) pre-junctional inhibition of the release of proinflammatory neuropeptides from sensory nerve terminals in the meninges; and (3) attenuation of central nociceptive neurotransmission by inhibition of neurotransmitter release within the trigeminal nucleus caudalis.

10 Sumatriptan succinate is indicated for the acute treatment of migraine attacks with or without aura in adults; it is a selective 5-hydroxytryptamine<sub>1</sub> receptor subtype agonist. Sumatriptan succinate is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1). Sumatriptan succinate is an acid addition salt of the free base sumatriptan.

15 Sumatriptan has the following structure (1):



(1).

20 The empirical formula of sumatriptan succinate is C<sub>14</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S•C<sub>4</sub>H<sub>6</sub>O<sub>4</sub>, representing a molecular weight of 413.5. Sumatriptan succinate is a white to off-white powder that is readily soluble in water and in saline.

In one approved dosage form, sumatriptan succinate is marketed in the United States for oral administration under the trademark IMITREX® in tablets containing 35, 70, or 140 mg of sumatriptan succinate, equivalent to 25, 50, or 100 mg of

25

5 sumatriptan, respectively. Liquid oral dosage forms and parenteral dosage forms have also been approved for use in the United States.

Sumatriptan relieves not only the pain of migraine, but also the associated symptoms of nausea, vomiting, light sensitivity (photophobia), and sound sensitivity  
10 (phonophobia). Many patients are able to continue to work or return to work after sumatriptan treatment, which often is not possible with ergotamine because of its sedating or nauseating effects.

Given the clinical advantages of sumatriptan, there is a continuing need for new dosage forms of that active ingredient that will facilitate its administration to  
15 patients in need and which will be less prone to adverse side effects associated with current sumatriptan products. For example, sumatriptan products that have increased solubility or bioavailability might very well cause fewer cardiovascular adverse incidents than known forms when administered to patients over the age of sixty-five.

## 20 SUMMARY OF THE INVENTION

The invention provides novel soluble sumatriptan crystalline forms that include salts, co-crystals, polymorphs, hydrates, and solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions  
25 comprising, and processes for making, these sumatriptan crystalline forms. Methods of using such compositions for the treatment or prevention of migraine headaches and related neurological disorders are also provided. In several embodiments, the invention provides novel soluble crystalline forms comprising: (a) a salt comprising the reaction product of sumatriptan and an organic or inorganic acid; (b) a solvate of  
30 sumatriptan or a solvate of a salt of sumatriptan; and (c) a polymorph of sumatriptan or a polymorph of a salt of sumatriptan.

Further, in an embodiment of the invention, two novel sumatriptan succinate polymorphs are characterized by powder X-ray diffraction patterns expressed in terms  
35 of 2-theta angles. In another embodiment, the present invention provides a

5 dichloromethane hemisolvate of sumatriptan succinate characterized by a powder X-ray diffraction pattern expressed in terms of 2-theta angles. In another embodiment, the present invention provides isobutanol, tetrahydrofuran, 1,2-dichloroethane, and dioxane solvates of sumatriptan succinate characterized by powder X-ray diffraction patterns expressed in terms of 2-theta angles.

10

The invention also provides pharmaceutical compositions comprising, and processes for making, these sumatriptan crystalline forms. Methods of using such compositions for the treatment or prevention of migraines and associated neurological disorders are also provided.

15

Compounds of the invention include, but are not limited to, soluble crystalline forms, including polymorphs, co-crystals, solvates, and hydrates of sumatriptan succinate, sumatriptan tartrate, sumatriptan citrate, sumatriptan fumarate, sumatriptan malonate, sumatriptan maleate, sumatriptan adipate, sumatriptan di-  
20 mesylate, sumatriptan sulfate, sumatriptan benzenesulfonate, or sumatriptan phosphate. Preferred soluble crystalline forms of the invention include dicarboxylic acid salts and hydrochloride acid salts of sumatriptan. Other preferred soluble crystalline forms include phosphoric acid, sulfuric acid or benzenesulfonic acid salts of sumatriptan.

25

Particularly preferred compounds of the invention include crystalline forms including polymorphs, co-crystals, solvates, and hydrates of sumatriptan succinate, sumatriptan tartrate, sumatriptan fumarate, sumatriptan citrate, sumatriptan malonate, sumatriptan maleate, sumatriptan adipate, or sumatriptan di-mesylate.

30

The invention further provides methods of treating or preventing migraines or associated neurological disorders in a patient by administration of therapeutically or prophylactically effective amounts of soluble crystalline forms of sumatriptan. Pharmaceutical dosage forms of the invention comprise therapeutically or  
35 prophylactically effective amounts of soluble crystalline forms of sumatriptan as disclosed herein.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the PXRD diffractogram of sumatriptan succinate form II.

10    Figure 2 shows the DSC thermograms of sumatriptan succinate form II (“New Form”) and form I (“Stable Form”).

Figure 3 shows the TGA thermograms of sumatriptan succinate form II (“New Form”) and form I (“Stable Form”).

15

Figure 4 shows the Raman spectra of sumatriptan succinate form II (upper spectrum; “New Form”) and form I (lower spectrum; “Stable Form”).

Figure 5 shows the PXRD diffractogram of sumatriptan succinate form III.

20

Figure 6 shows predicted and experimental PXRD diffractograms of sumatriptan succinate form I.

Figures 7A-7C show packing diagrams for sumatriptan succinate form I derived from  
25    single-crystal x-ray analysis.

Figure 8 shows the PXRD diffractogram of sumatriptan succinate dichloromethane hemisolvate.

30    Figure 9 shows the DSC thermograms of sumatriptan succinate dichloromethane hemisolvate (solid line; upper trace) and sumatriptan succinate (form I; dashed line; lower trace).

Figure 10 shows the TGA thermogram of sumatriptan succinate dichloromethane  
35    hemisolvate.

5 Figure 11 shows the PXRD diffractogram of sumatriptan succinate isobutanol solvate.

Figure 12 shows the PXRD diffractogram of sumatriptan succinate 1,4-dioxane solvate.

10 Figure 13 shows the PXRD diffractogram of sumatriptan succinate tetrahydrofuran solvate.

Figure 14 shows the PXRD diffractogram of sumatriptan succinate 1,2-dichloroethane solvate.

15

### DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following terms have the following respective meanings.

20 As used herein, the term “solvate” is a complex of variable stoichiometry formed by a solute (sumatriptan or salts, co-crystals, hydrates, or polymorphs of sumatriptan) and an organic solvent as defined herein, including an alcohol.

25 “Organic or inorganic acids” include, but are not limited to, succinic acid, carboxylic acids, dicarboxylic acids, hydrochloric acid, phosphoric acid, sulfuric acid, benzenesulfonic acid, methanesulfonic acid, and, in general terms, any acidic species that will form a thermodynamically stable crystalline (salt) form upon reaction with the free base sumatriptan.

30 The term “co-crystal” as used herein means a crystalline material comprised of two or more unique solids at room temperature, each containing distinctive physical characteristics, such as structure, melting point, and heats of fusion, with the exception that, if specifically stated, the API (active pharmaceutical ingredient) may be a liquid at room temperature. The co-crystals of the present invention comprise a  
35 co-crystal former H-bonded to sumatriptan or a salt, hydrate, or solvate thereof. The co-crystal former may be H-bonded directly to a soluble crystalline form of the

5 present invention or may be H-bonded to an additional molecule which is bound to a soluble crystalline form of the present invention. The additional molecule may be H-bonded to a soluble crystalline form or bound ionically or covalently to a soluble crystalline form. The additional molecule could also be a different API. Solvates of soluble crystalline forms of sumatriptan that do not further comprise a co-crystal  
10 former are not co-crystals according to the present invention. The co-crystals may however, include one or more solvate molecules in the crystalline lattice. That is, solvates of co-crystals, or a co-crystal further comprising a solvent or compound that is a liquid at room temperature, is included in the present invention, but crystalline material comprised of only a soluble crystalline form of sumatriptan and one or more  
15 liquids (at room temperature) are not included in the present invention. Other modes of molecular recognition may also be present including, pi-stacking, guest-host complexation and van der Waals interactions. Of the interactions listed above, hydrogen-bonding is the dominant interaction in the formation of the co-crystal, (and a required interaction according to the present invention) whereby a non-covalent  
20 bond is formed between a hydrogen bond donor of one of the moieties and a hydrogen bond acceptor of the other. Hydrogen bonding can result in several different intermolecular configurations. For example, hydrogen bonds can result in the formation of dimers, linear chains, or cyclic structures. These configurations can further include extended (two-dimensional) hydrogen bond networks and isolated  
25 triads. An alternative embodiment provides for a co-crystal wherein the co-crystal former is a second API. In another embodiment, the co-crystal former is not an API. For purposes of the present invention, the chemical and physical properties of soluble crystalline forms of sumatriptan in the form of a co-crystal may be compared to a reference compound that is sumatriptan in a different form. The reference compound  
30 may be specified as a free form, or more specifically, an anhydrate or hydrate of a free form, or more specifically, for example, a hemihydrate, monohydrate, dihydrate, trihydrate, quadrahydrate, pentahydrate; or a solvate of a free form. For example, the reference compound for sumatriptan succinate co-crystallized with a co-crystal former can be sumatriptan succinate in free form. The reference compound may also be  
35 specified as crystalline or amorphous. The reference compound may also be specified as the most stable polymorph of the specified form of the reference compound.

5

“Soluble crystalline forms” encompass crystalline species including salts, hydrates, solvates, co-crystals or polymorphs that are soluble in aqueous media at values greater than 5 micrograms/mL, more preferably greater than 10 micrograms/mL, more preferably greater than 20 micrograms/mL, more preferably greater than 30 micrograms/mL, more preferably greater than 40 micrograms/mL, more preferably greater than 50 micrograms/mL, and most preferably greater than 100 micrograms/mL in a solution with a pH of about 1. Soluble crystalline forms can comprise: (a) a salt comprising the reaction product of sumatriptan and an organic acid or an inorganic acid; (b) a solvate of sumatriptan or a solvate of a salt of sumatriptan; and (c) a polymorph of sumatriptan or a polymorph of a salt of sumatriptan.

“Organic solvent” includes, but is not limited to, 1,4-dioxane (dioxane), 1,2-dichloroethane, dimethoxyethane, diethylene glycol dimethyl ether, tetrahydrofuran, diisopropyl ether, hydrocarbons such as hexane, heptane, cyclohexane, toluene or xylene, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, tert-butanol or ethylene glycol, ketones such as methyl ethyl ketone or isobutyl methyl ketone, amides such as dimethylformamide, dimethylacetamide or N-methylpyrrolidone, and mixtures thereof.

25

As used herein, the terms “stereoisomer” or “stereoisomeric form” means compounds having a stereoisomeric purity of at least 90%, and preferably at least 95% up to a stereoisomeric purity of 100% by weight, preferably compounds having a stereoisomeric purity of at least 97% up to a stereoisomeric purity of 100%, and more preferably having a stereoisomeric purity of at least 99% up to a stereoisomeric purity of 100% by weight.

30

As used herein, the term “adjunctively administered” refers to the administration of one or more compounds or active ingredients in addition to a pharmaceutically acceptable crystalline form of sumatriptan, either simultaneously or at intervals prior to, during, or following administration of the pharmaceutically

35

5 acceptable salt of sumatriptan to achieve the desired therapeutic or prophylactic effect.

As used herein, the term “pharmaceutically acceptable salt” refers to a salt prepared from pharmacologically acceptable anions, such as, but not limited to,  
10 hydrochloride, phosphate, formate, adipate, succinate, fumarate, malate, tartrate, malonate, maleate, mesylate and benzenesulfonate. Particularly preferred anions are tartrate, benzenesulfonate, malate, succinate, hydrobromide, bitartrate, *para*-toluenesulfonate, glycolate, glucuronate, mucate, gentisate, isonicotinate, saccharate, phosphate, hydroiodide, nitrate, sulfate, bisulfate, acetate, propionate,  
15 camphorsulfonate, gluconate, isothionate, lactate, furoate, glutamate, ascorbate, benzoate, anthranilate, salicylate, phentylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, pantothenate, stearate, sulfanilate, alginate, *p*-toluenesulfonate, mesylate, and galacturonate.

20 As used herein, the term “method of treating or preventing a migraine or associated neurological disorder” means prevention of, or relief from symptoms including a severe, throbbing headache, related sensory, motor or visual symptoms, possibly including an “aura” as well as nausea and or vomiting or sensitivity to light and noise, or both.

25

In certain embodiments, the novel soluble crystalline forms of sumatriptan have a solubility greater than 5 micrograms/mL, more preferably greater than 10 micrograms/mL, more preferably greater than 20 micrograms/mL, more preferably greater than 30 micrograms/mL, more preferably greater than 40 micrograms/mL,  
30 more preferably greater than 50 micrograms/mL, and most preferably greater than 100 micrograms/mL in a solution with a pH of about 1.

Preferred pharmaceutical compositions of the invention comprise a therapeutically effective amount of a novel soluble crystalline form comprising: (a) a  
35 salt comprising the reaction product of sumatriptan and an organic or inorganic acid;

- 5 (b) a solvate of sumatriptan or a solvate of a salt of sumatriptan; and (c) a polymorph of sumatriptan or a polymorph of a salt of sumatriptan.

A further embodiment of the invention encompasses a method of treating or preventing a migraine or associated neurological disorder in a patient which  
10 comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a pharmaceutically acceptable soluble crystalline form of sumatriptan. More specifically, the invention includes a method for treating or preventing a migraine or associated neurological disorder in a patient comprising administering to a patient in need of such treatment or prevention,  
15 a therapeutically or prophylactically effective amount of a soluble crystalline form of sumatriptan such as sumatriptan succinate, di-mesylate, sumatriptan tartrate, sumatriptan fumarate, sumatriptan malonate, sumatriptan maleate, sumatriptan adipate, or sumatriptan malate.

20 Sumatriptan succinate is commercially available as a solid dosage form. Sumatriptan succinate, the active ingredient in IMITREX® (marketed by GlaxoSmithKline), is present as a crystalline form herein referred to as form I. Sumatriptan succinate (form I) is described in US Patent No. 5,037,845. The present invention provides novel pharmaceutically acceptable forms of sumatriptan including  
25 the succinic acid salt of sumatriptan.

Further, in an embodiment of the invention, two novel sumatriptan succinate polymorphs are characterized by powder X-ray diffraction pattern expressed in terms of 2 theta angles. In another embodiment, the present invention provides a  
30 dichloromethane hemisolvate of sumatriptan succinate. In another embodiment, the present invention provides isobutanol, tetrahydrofuran, 1,2-dichloroethane, and dioxane solvates of sumatriptan succinate.

In another embodiment, a method is provided of altering the crystal form of a  
35 soluble crystalline form of sumatriptan by changing a parameter selected from the group consisting of vial shape, vial material, cooling rate, vial treatment, mixing rate,

5 thermal cycling, and dispense method. Vials can be treated with a solvent or a solution such as, but not limited to, acetone or a base solution. Initially, the salt can be dispensed as a solid or as a liquid by dissolving the salt in solution. In another embodiment, a method for altering the crystal form of a soluble crystalline form of sumatriptan comprises altering the size and/or shape of the salt solution container. In  
10 another embodiment, a method for altering the crystal form of a soluble crystalline form of sumatriptan comprises increasing the cooling rate of the salt solution. In another embodiment, a method for altering the crystal form of a soluble crystalline form of sumatriptan comprises treating the salt solution container with a solvent or solution. In another embodiment, a method for altering the crystal form of a soluble  
15 crystalline form of sumatriptan comprises altering the mixing rate of the salt solution.

#### Pharmaceutical Compositions and Dosage Forms

Pharmaceutical dosage forms of the invention comprise a therapeutically or prophylactically effective amount of a novel soluble crystalline form of sumatriptan,  
20 including hydrates, solvates or polymorphs thereof. These dosage forms also comprise a soluble, multicomponent crystalline system comprising a sumatriptan organic salt. These compositions can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. Oral and parenteral pharmaceutical compositions and dosage forms are a  
25 preferred dosage form. Preferably, the oral dosage form is a solid dosage form, such as a tablet, a caplet, a hard gelatin capsule, a starch capsule, a hydroxypropyl methylcellulose (HPMC) capsule, or a soft elastic gelatin capsule. Other preferred dosage forms include an intradermal dosage form, an intramuscular dosage form, a subcutaneous dosage form, and an intravenous dosage form.

30

Pharmaceutical compositions and dosage forms of the invention comprise an active ingredient as disclosed herein, e.g., an acid salt such as sumatriptan succinate or a soluble, multicomponent crystalline system comprising a sumatriptan organic salt optionally including an organic solvent. Pharmaceutical compositions and unit  
35 dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients or diluents. In one embodiment, the pharmaceutical

5 compositions and unit dosage forms of the invention typically also comprise one or more pharmaceutically acceptable excipients or diluents, wherein at least one of the pharmaceutically acceptable excipients or diluents is an antioxidant.

Pharmaceutical unit dosage forms of this invention are suitable for oral,  
10 mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., intramuscular, subcutaneous, intravenous, intraarterial, or bolus injection), topical, or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets, caplets, capsules, such as hard gelatin capsules, starch capsules, hydroxypropyl methylcellulose (HPMC) capsules, and soft elastic gelatin capsules,  
15 cachets, troches, lozenges, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, plasters, solutions, patches, aerosols (e.g., nasal sprays or inhalers), gels, liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and  
20 elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.

The composition, shape, and type of dosage forms of the invention will  
25 typically vary depending on their use. For example, a dosage form used in the acute treatment of a disease or disorder may contain larger amounts of the active ingredient than a dosage form used in the chronic treatment of the same disease or disorder. Similarly, a parenteral dosage form may contain smaller amounts of the active ingredient than an oral dosage form used to treat the same disease or disorder. These  
30 and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990) or Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing, Easton PA (1995).

5           Typical pharmaceutical compositions and dosage forms comprise one or more excipients. Suitable excipients are well known to those skilled in the art of pharmacy, and non-limiting examples of suitable excipients are provided herein. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not  
10   limited to, the way in which the dosage form will be administered to a patient. For example, oral dosage forms such as tablets or capsules may contain excipients not suited for use in parenteral dosage forms. In addition, pharmaceutical compositions or dosage forms may contain one or more compounds that reduce or alter the rate by which the active ingredient will decompose. Such compounds, which are referred to  
15   herein as “stabilizers”, include, but are not limited to, antioxidants, pH buffers, or salt buffers.

          One or more antioxidants can be used in pharmaceutical compositions and dosage forms to deter radical oxidation of the active ingredient, wherein such  
20   antioxidants include, but are not limited to, ascorbic acid, phenolic antioxidants including, but not limited to, butylated hydroxyanisole (BHA) and propyl gallate, and chelators including, but not limited to citrate, EDTA, and DTPA. Preferably, in cases where radical oxidation of the active ingredient is known to occur, a combination of phenolic antioxidants and chelators can be used.

25           Like the amounts and types of excipients, the amounts and specific type of active ingredient in a dosage form may differ depending on factors such as, but not limited to, the route by which it is to be administered to patients. However, typical dosage forms of the invention comprise a pharmaceutically acceptable soluble  
30   crystalline form of sumatriptan or its stereoisomers, selected from the group consisting of sumatriptan succinate and sumatriptan-HCl, and pharmaceutically acceptable hydrates, solvates, polymorphs, and co-crystals thereof, in an amount ranging from about 10 mg to about 1000 mg, preferably in an amount ranging from about 25 mg to about 500 mg, more preferably in an amount of from 40 mg to 400  
35   mg, and most preferably in an amount of from about 50 mg to about 200 mg.

5 Oral Dosage Forms

Pharmaceutical compositions of the invention that are suitable for oral administration can be presented as discrete dosage forms, such as, but not limited to, tablets (including without limitation scored or coated tablets), pills, caplets, capsules (including without limitation hard gelatin capsules, starch capsules, HPMC capsules, 10 and soft elastic gelatin capsules), chewable tablets, powder packets, sachets, troches, wafers, aerosol sprays, or liquids, such as but not limited to, syrups, elixirs, solutions or suspensions in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil emulsion. Such compositions contain a predetermined amount of the active ingredient, and may be prepared by methods of pharmacy well known to those 15 skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton, PA (1990) or Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing, Easton, PA (1995).

Typical oral dosage forms of the invention are prepared by combining the 20 active ingredient in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques. Excipients can take a wide variety of forms depending on the form of the composition desired for administration. For example, excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, 25 preservatives, and coloring agents. Examples of excipients suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, microcrystalline cellulose, kaolin, diluents, granulating agents, lubricants, binders, stabilizers, and disintegrating agents.

30 Due to their ease of administration, tablets, caplets, and capsules (such as hard gelatin, HPMC, or starch capsules) represent the most advantageous solid oral dosage unit forms, in which case solid pharmaceutical excipients are used. If desired, tablets or caplets can be coated by standard aqueous or nonaqueous techniques. These dosage forms can be prepared by any of the methods of pharmacy. In general, 35 pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredient(s) with liquid carriers, finely divided solid

5 carriers, or both, and then shaping the product into the desired presentation if necessary.

For example, a tablet can be prepared by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active  
10 ingredient(s) in a free-flowing form, such as a powder or granules, optionally mixed with one or more excipients. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

Examples of excipients that can be used in oral dosage forms of the invention  
15 include, but are not limited to, binders, stabilizers, fillers, disintegrants, and lubricants. Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl  
20 cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.

25 Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, and AVICEL-PH-105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, PA, U.S.A.), and mixtures thereof. An exemplary suitable binder is a mixture of microcrystalline cellulose and sodium carboxymethyl  
30 cellulose sold as AVICEL RC-581. Suitable anhydrous or low moisture excipients or additives include AVICEL-PH-103<sup>TM</sup> and Starch 1500 LM.

Examples of fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate  
35 (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures

5    thereof. The binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.

10    Disintegrants can be used in the pharmaceutical compositions and dosage forms to provide tablets or caplets that disintegrate when exposed to an aqueous environment. Tablets or caplets that contain too much disintegrant may disintegrate in storage, while those that contain too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor  
15    too much to control the release of the active ingredient(s) should be used to form solid oral dosage forms of the invention. The amount of disintegrant used varies based upon the type of formulation and mode of administration, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, preferably from about 1 to about  
20    5 weight percent of disintegrant.

Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone,  
25    polacrillin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, other algin, other celluloses, gums, and mixtures thereof.

Antioxidants can be used in the pharmaceutical compositions and dosage  
30    forms to deter degradation or radical oxidation of the active ingredient. Examples of suitable antioxidants include, but are not limited to, ascorbic acid, phenolic antioxidants including, but not limited to, butylated hydroxyanisole (BHA) and propyl gallate, and chelators including, but not limited to, citrate, EDTA, and DTPA, or combinations thereof.

5 Lubricants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and  
10 soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Plano, TX), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures thereof. If  
15 used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.

Other oral dosage forms for pharmaceutical compositions of the invention are  
20 soft elastic gelatin capsules. Soft elastic gelatin capsule unit dosage forms can be made using conventional methods well known in the art. See, e.g., Ebert, Pharm. Tech, 1(5):44-50 (1977). In general, soft elastic gelatin capsules (also known as soft gels) have an elastic or soft, globular or oval shaped gelatin shell that is typically a bit thicker than that of hard gelatin capsules, wherein a plasticizing agent, e.g., glycerin,  
25 sorbitol, or a similar polyol, is added to a gelatin. The type of gelatin, as well as the amounts of plasticizer and water, can be used to vary the hardness of the capsule shell. The soft gelatin shells may contain a preservative, such as methyl- and propylparabens and sorbic acid, to prevent the growth of fungi. The active ingredient may be dissolved or suspended in a liquid vehicle or carrier, such as vegetable or  
30 mineral oils, glycols, such as polyethylene glycol and propylene glycol, triglycerides, surfactants, such as polysorbates, or a combination thereof.

5     Controlled Release Dosage Forms

Pharmaceutically acceptable soluble crystalline forms of sumatriptan can be administered by controlled- or delayed-release means. Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts. Ideally, the use of an optimally  
10     designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include: 1) extended activity of the drug; 2) reduced dosage frequency; 3) increased patient compliance; 4) usage of less total drug; 5) reduction in local or systemic side effects;  
15     6) minimization of drug accumulation; 7) reduction in blood level fluctuations; 8) improvement in efficacy of treatment; 9) reduction of potentiation or loss of drug activity; and 10) improvement in speed of control of diseases or conditions. (Kim, Cherng-ju, Controlled Release Dosage Form Design, 2 Technomic Publishing, Lancaster, Pa.: 2000).

20

Conventional dosage forms generally provide rapid or immediate drug release from the formulation. Depending on the pharmacology and pharmacokinetics of the drug, use of conventional dosage forms can lead to wide fluctuations in the concentrations of the drug in a patient's blood and other tissues. These fluctuations  
25     can impact a number of parameters, such as dose frequency, onset of action, duration of efficacy, maintenance of therapeutic blood levels, toxicity, side effects, and the like. Advantageously, controlled-release formulations can be used to control a drug's onset of action, duration of action, plasma levels within the therapeutic window, and peak blood levels. In particular, controlled- or extended-release dosage forms or  
30     formulations can be used to ensure that the maximum effectiveness of a drug is achieved while minimizing potential adverse effects and safety concerns, which can occur both from under dosing a drug (i.e., going below the minimum therapeutic levels) as well as exceeding the toxicity level for the drug.

35     Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic

5 effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated  
10 by various conditions including, but not limited to, pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.

A variety of known controlled- or extended-release dosage forms,  
15 formulations, and devices can be adapted for use with the soluble crystalline forms and compositions of the invention. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,733,566; and 6,365,185 B1; each of which is incorporated herein by reference.  
20 These dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS® (Alza Corporation, Mountain View, Calif. USA)), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release  
25 profile in varying proportions. Additionally, ion exchange materials can be used to prepare immobilized, adsorbed soluble crystalline forms and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite® A568 and Duolite® AP143 (Rohm & Haas, Spring House, PA. USA).

30

One embodiment of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable soluble crystalline form of sumatriptan (e.g., sumatriptan succinate), and one or more pharmaceutically acceptable excipients or diluents, wherein the pharmaceutical composition or dosage form is formulated for  
35 controlled-release. Specific dosage forms utilize an osmotic drug delivery system.

5 A particular and well-known osmotic drug delivery system is referred to as OROS® (Alza Corporation, Mountain View, Calif. USA). This technology can readily be adapted for the delivery of compounds and compositions of the invention. Various aspects of the technology are disclosed in U.S. Pat. Nos. 6,375,978 B1; 6,368,626 B1; 6,342,249 B1; 6,333,050 B2; 6,287,295 B1; 6,283,953 B1; 6,270,787  
10 B1; 6,245,357 B1; and 6,132,420; each of which is incorporated herein by reference. Specific adaptations of OROS® that can be used to administer compounds and compositions of the invention include, but are not limited to, the OROS® Push-Pull™, Delayed Push-Pull™, Multi-Layer Push-Pull™, and Push-Stick™ Systems, all of which are well known. See, e.g., <http://www.alza.com>. Additional OROS®  
15 systems that can be used for the controlled oral delivery of compounds and compositions of the invention include OROS®-CT and L-OROS®. Id.; see also, Delivery Times, vol. II, issue II (Alza Corporation).

Conventional OROS® oral dosage forms are made by compressing a drug  
20 powder (e.g., sumatriptan succinate) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e.g., with a laser). (Kim, Chong-ju, Controlled Release Dosage Form Design, 231-238 Technomic Publishing, Lancaster, Pa.: 2000). The advantage of such dosage forms is that the delivery rate of the drug is not influenced by physiological or  
25 experimental conditions. Even a drug with a pH-dependent solubility can be delivered at a constant rate regardless of the pH of the delivery medium. But because these advantages are provided by a build-up of osmotic pressure within the dosage form after administration, conventional OROS® drug delivery systems cannot be used to effectively deliver drugs with low water solubility.

30 A specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the  
35 wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable

5 layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a soluble crystalline form of the present invention. See U.S. Pat. No. 6,368,626, the entirety of which is incorporated herein by reference.

10 Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and  
15 in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug  
20 layer, wherein the active agent formulation comprises a soluble crystalline form of sumatriptan. See U.S. Pat. No. 6,342,249, the entirety of which is incorporated herein by reference.

#### Topical Dosage Forms

25 Topical dosage forms of the invention include, but are not limited to, creams, lotions, ointments, gels, shampoos, sprays, aerosols, solutions, emulsions, and other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 18<sup>th</sup> ed., Mack Publishing, Easton, PA (1990); and Introduction to Pharmaceutical Dosage Forms, 4<sup>th</sup> ed., Lea & Febiger, Philadelphia, PA (1985). For non-sprayable  
30 topical dosage forms, viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than water are typically employed. Suitable formulations include, without limitation, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with  
35 auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure. Other suitable

5 topical dosage forms include sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as freon), or in a squeeze bottle. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients  
10 are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 18<sup>th</sup> ed., Mack Publishing, Easton, PA (1990).

#### Parenteral Dosage Forms

Parenteral dosage forms can be administered to patients by various routes,  
15 including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial. Since administration of parenteral dosage forms typically bypasses the patient's natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not  
20 limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.

Suitable vehicles that can be used to provide parenteral dosage forms of the  
25 invention are well known to those skilled in the art. Examples include, without limitation: sterile water; Water for Injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol,  
30 polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. The solutions are preferably isotonic and have a physiological pH.

35 Compounds that increase the solubility of the active ingredient(s) disclosed herein can also be incorporated into the parenteral dosage forms of the invention.

5

Transdermal and Mucosal Dosage Forms

Transdermal and mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, patches, sprays, aerosols, creams, lotions, suppositories, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 18<sup>th</sup> ed., Mack Publishing, Easton, PA (1990); and Introduction to Pharmaceutical Dosage Forms, 4<sup>th</sup> ed., Lea & Febiger, Philadelphia, PA (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes, as oral gels, or as buccal patches. Further, transdermal dosage forms include "reservoir type" or "matrix type" patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredient.

Suitable excipients (e.g., carriers and diluents) and other materials that can be used to provide transdermal and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue or organ to which a given pharmaceutical composition or dosage form will be applied. With that fact in mind, typical excipients include, but are not limited to water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof, to form dosage forms that are non-toxic and pharmaceutically acceptable.

Depending on the specific tissue to be treated, additional components may be used prior to, in conjunction with, or subsequent to treatment with active ingredients of the invention. For example, penetration enhancers can be used to assist in delivering the active ingredients to or across the tissue. Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various

- 5 water-soluble or insoluble sugar esters such as TWEEN 80 (polysorbate 80) and SPAN 60 (sorbitan monostearate).

The pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied, may also be adjusted to improve delivery of the active ingredient(s). Similarly, the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery. Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of the active ingredient(s) so as to improve delivery. In this regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent. Different hydrates, solvates, polymorphs, or co-crystals of the active ingredient can be used to further adjust the properties of the resulting composition.

20 In another embodiment, the present invention provides a combination oral dosage form and transdermal dosage form of a soluble crystalline form of sumatriptan. This embodiment provides an initial rapid onset for acute migraine treatment followed by a level of sustained release to prevent or decrease the reoccurrence of migraine. In one embodiment, the blood plasma concentration of a soluble crystalline form of sumatriptan released in a sustained manner is less than that of the initially released therapeutic agent. In another embodiment, the blood plasma concentration of a soluble crystalline form of sumatriptan released in a sustained manner is about equal to that of the initially released therapeutic agent.

### 30 Methods Of Treatment and Prevention

Pharmaceutically acceptable salts, co-crystals, and polymorphs of sumatriptan, and pharmaceutical compositions and dosage forms thereof, should possess potent activity against, and are useful for treating or preventing, a migraine or associated neurological disorder. For example, pharmaceutically acceptable soluble crystalline form of sumatriptan, and pharmaceutical compositions and dosage forms thereof, can be used to treat or prevent a severe, throbbing headache, related sensory, motor or

- 5 visual symptoms, including an “aura” as well as nausea and or vomiting or sensitivity to light and noise, or both.

The magnitude of a prophylactic or therapeutic dose of each active ingredient in the acute or chronic management of a disease or disorder will vary with the disease  
10 or disorder itself, the specific active ingredients, and the route of administration. The dose, dose frequency, or both, may also vary according to age, body weight, response, the past medical history of the patient, and consideration of whether the patient is or will be concurrently or concomitantly taking other drugs or pharmaceuticals. Suitable dosing regimens can be readily selected by the skilled artisan with due consideration  
15 of such factors by following, for example, dosages and dose regimens reported in the literature and recommended in the Physician’s Desk Reference® (56<sup>th</sup> ed., 2002) for itraconazole. Unless otherwise indicated, the magnitude of a prophylactic or therapeutic dose of the active ingredient used in an embodiment of the invention will be that which is safe and effective (e.g., has received regulatory approval).

20

In one embodiment of the invention, the active ingredient (e.g., soluble crystalline forms of sumatriptan succinate, sumatriptan di-mesylate, sumatriptan tartrate, sumatriptan fumarate, sumatriptan malonate, sumatriptan maleate, sumatriptan adipate, sumatriptan malate, sumatriptan-HCl, sumatriptan phosphate,  
25 sumatriptan sulfate or sumatriptan benzenesulfonate, or multicomponent crystalline systems, hydrates, solvates, polymorphs, or co-crystals thereof) is administered orally as needed in an amount of from about 10 mg to about 1000 mg, preferably in an amount of from about 25 mg to about 500 mg, more preferably in an amount from about 40 mg to about 400 mg, and most preferably in an amount of from about 50 mg  
30 to about 200 mg. The dosage amounts can be administered in single or divided doses. The dosage amounts and frequencies provided above are encompassed by the terms “therapeutically effective”, “prophylactically effective”, and “therapeutically or prophylactically effective” as used herein.

35 The suitability of a particular route of administration employed for a particular active ingredient will depend on the active ingredient itself (e.g., whether it can be

5 administered orally without decomposing prior to entering the blood stream) and the disease or disorder to be treated or prevented. For example, oral or parenteral administration is typically preferred for treating or preventing a severe, throbbing headache, related sensory, motor or visual symptoms, including an "aura", as well as nausea and or vomiting or sensitivity to light and noise, or both. Similarly, oral or  
10 parenteral administration may be preferred for the treatment or prevention of migraine, whereas transdermal or subcutaneous routes of administration may be employed for treatment or prevention of chronic migraines or associated disorders.

Preparation of sumatriptan and related pharmaceutically acceptable salts

15 Sumatriptan and related pharmaceutically acceptable salts can be made using various methods known to those skilled in the art. Processes for making sumatriptan and related pharmaceutically acceptable salts are disclosed in United States Patent Nos. 4,816,470 and 5,037,845, the complete disclosures of which are hereby incorporated by reference.

20

Salts, co-crystals, or organic salts of sumatriptan, including without limitation, pharmaceutically acceptable salts can be prepared by treating sumatriptan free base with appropriate acids, such as organic or inorganic acids, including without limitation, succinic acid, malic acid, hydrochloric acid, sulfuric acid, fumaric acid,  
25 phosphoric acid, tartaric acid, maleic acid, malonic acid, adipic acid, benzenesulfonic acid, and the like. For example, the process for forming a salt and co-crystal can be carried out in a solvent system in which both reactants (i.e., sumatriptan free base and the respective acid) are sufficiently soluble.

30 In one method, in order to achieve crystallization or precipitation, a solvent or solvent mixture in which the resulting salt and co-crystal is only slightly soluble or not soluble at all is used. Alternatively, supersaturated solutions of sumatriptan succinate may be prepared by increasing the temperature of the solvent mixture in the presence of sumatriptan succinate, then decreasing the temperature; forms of  
35 sumatriptan succinate will then recrystallize spontaneously. Alternatively, a solvent in which the desired salt and co-crystal is very soluble can be used, and then an anti-

5 solvent (or a solvent in which the resulting salt is poorly soluble) is added to the  
solution. Other variants for salt formation or crystallization include concentrating the  
salt and co-crystal solution (e.g., by heating, under reduced pressure if necessary, or  
by slowly evaporating the solvent, for example, at room temperature), or seeding with  
the addition of seed crystals, or setting up water activity required for hydrate  
10 formation.

The invention is further defined by reference to the following examples. It will  
be apparent to those skilled in the art that many modifications, both to materials and  
methods, can be practiced without departing from the scope of this invention.

15

## EXEMPLIFICATION

### Analytical Methods

#### Procedure for DSC analysis

DSC analysis of the samples was performed using a Q1000 Differential  
20 Scanning Calorimeter (TA Instruments, New Castle, DE, U.S.A.), which uses  
Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (2001  
TA Instruments-Water LLC). In addition, the analysis software used was Universal  
Analysis 2000 for Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (2001 TA  
Instruments-Water LLC).

25

For the DSC analysis, the purge gas used was dry nitrogen, the reference  
material was an empty aluminum pan that was crimped, and the sample purge was 50  
mL/minute.

30 DSC analysis of the sample was performed by placing  $\leq 2$  mg of sample in an  
aluminum pan with a crimped pan closure. The starting temperature was typically 20  
degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was  
300 degrees C. Unless otherwise indicated, all reported transitions are as stated +/-  
1.0 degrees C.

35

5     Procedure for TGA analysis

TGA analysis of samples was performed using a Q500 Thermogravimetric Analyzer (TA Instruments, New Castle, DE, U.S.A.), which uses Advantage for QW-Series, version 1.0.0.78, Thermal Advantage Release 2.0 (2001 TA Instruments-Water LLC). In addition, the analysis software used was Universal Analysis 2000 for  
10   Windows 95/95/2000/NT, version 3.1E;Build 3.1.0.40 (2001 TA Instruments-Water LLC).

For all of the TGA experiments, the purge gas used was dry nitrogen, the balance purge was 40 mL/minute N<sub>2</sub>, and the sample purge was 60 mL/minute N<sub>2</sub>.

15

TGA of the sample was performed by placing  $\leq 2$  mg of sample in a platinum pan. The starting temperature was typically 20 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 300 degrees C.

20     Procedure for PXRD analysis

A powder X-ray diffraction pattern for the samples was obtained using a D/Max Rapid, Contact (Rigaku/MS, The Woodlands, TX, U.S.A.), which uses as its control software RINT Rapid Control software, Rigaku Rapid/XRD, version 1.0.0 (1999 Rigaku Co.). In addition, the analysis software used were RINT Rapid display  
25   software, version 1.18 (Rigaku/MS), and JADE XRD Pattern Processing, versions 5.0 and 6.0 ((1995-2002, Materials Data, Inc.).

For the PXRD analysis, the acquisition parameters were as follows: source was Cu with a K line at 1.5406Å; x-y stage was manual; collimator size was 0.3 or 0.8  
30   mm; capillary tube (Charles Supper Company, Natick, MA, U.S.A.) was 0.3 mm ID; reflection mode was used; the power to the X-ray tube was 46 kV; the current to the X-ray tube was 40 mA; the omega-axis was oscillating in a range of 0-5 degrees at a speed of 1 degree/minute; the phi-axis was spinning at an angle of 360 degrees at a speed of 2 degrees/second; 0.3 or 0.8 mm collimator; the collection time was 60  
35   minutes; the temperature was room temperature; and the heater was not used. The sample was presented to the X-ray source in a boron rich glass capillary.

5

In addition, the analysis parameters were as follows: the integration 2-theta range was 2-40 or 60 degrees; the integration chi range was 0-360 degrees; the number of chi segments was 1; the step size used was 0.02; the integration utility was cylint; normalization was used; dark counts were 8; omega offset was 180; and chi and phi offsets were 0.

10

The relative intensity of peaks in a diffractogram is not necessarily a limitation of the PXRD pattern because peak intensity can vary from sample to sample, e.g., due to crystalline impurities. Further, the angles of each peak can vary by about +/- 0.1 degrees, preferably +/-0.05. The entire pattern or most of the pattern peaks may also shift by about +/- 0.1 degree due to differences in calibration, settings, and other variations from instrument to instrument and from operator to operator.

15

#### Procedure for Raman Acquisition, Filtering and Binning

20

##### *Acquisition*

25

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega™ Dispersive Raman (Almega™ Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table I. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

30

##### *Filtering and Binning*

35

Each spectrum in a set was filtered using a matched filter of feature size 25 to remove background signals, including glass contributions and sample fluorescence. This is particularly important as large background signal or fluorescence limit the ability to accurately pick and assign peak positions in the subsequent steps of the binning process. Filtered spectra were binned using the peak pick and bin algorithm

- 5 with the parameters given in Table II. The sorted cluster diagrams for each sample set and the corresponding cluster assignments for each spectral file were used to identify groups of samples with similar spectra, which were used to identify samples for secondary analyses.

10 Table I. Raman Spectral acquisition parameters

Parameter	Setting Used
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (um)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition (degrees C)	24.0

Table II. Raman Filtering and Binning Parameters

Parameter	Setting Used
<i>Filtering Parameters</i>	
Filter type	Matched
Filter size	25
<i>QC Parameters</i>	
Peak Height Threshold	1000
Region for noise test (cm <sup>-1</sup> )	0-10000
RMS noise threshold	10000
Automatically eliminate failed spectra	Yes
<i>Region of Interest</i>	
Include (cm <sup>-1</sup> )	104-3428
Exclude region I (cm <sup>-1</sup> )	
Exclude region II (cm <sup>-1</sup> )	
Exclude region III (cm <sup>-1</sup> )	
Exclude region IV (cm <sup>-1</sup> )	
<i>Peak Pick Parameters</i>	
Peak Pick Sensitivity	Variable
Peak Pick Threshold	100
<i>Peak Comparison Parameters</i>	
Peak Window (cm <sup>-1</sup> )	2
<i>Analysis Parameters</i>	
Number of clusters	Variable

5

### Procedure for Single Crystal X-Ray Diffraction

Single crystal x-ray data were collected on a Bruker SMART-APEX CCD diffractometer (M. J. Zaworotko, Department of Chemistry, University of South  
10 Florida). Lattice parameters were determined from least squares analysis. Reflection data was integrated using the program SAINT. The structure was solved by direct methods and refined by full matrix least squares using the program SHELXTL (Sheldrick, G. M. SHELXTL, Release 5.03; Siemens Analytical X-ray Instruments Inc.: Madison, WI).

15

The soluble crystalline forms of the present invention can be characterized, e.g., by the TGA or DSC data or by any one, any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, or any single integer number of PXRD 2-theta angle peaks or Raman shift peaks listed herein or disclosed in a figure,  
20 or by single crystal x-ray diffraction data.

### EXAMPLE 1

#### 25 SYNTHESIS AND ANALYSIS OF SUMATRIPTAN SUCCINATE (FORM II)

Approximately 25 microliters of an approximately 50 mg/ml solution of a sumatriptan succinate stock sample dissolved in approximately 9:1 volume:volume (v/v) water:methanol was dispersed in a 1 mL tube to form a reaction medium. The resulting reaction medium was evaporated until dry. Approximately 500 microliters  
30 of an approximately 2:1 v/v mixture of anisole and p-dioxane was added to the reaction medium and the reaction medium was heated to approximately 60 degrees C, and then rapidly cooled to approximately 5 degrees C by immersion in ice water. This heating and cooling procedure was repeated twice (cooling more slowly in the second iteration), and the tube was incubated for one to two days between cycles.  
35 The resultant sumatriptan succinate polymorph (designated as "Form II") was isolated by extracting the supernatant with a syringe, followed by drying under flowing nitrogen.

5

A beaker of distilled water was prepared and the pH of the water was measured. A sample of the isolated sumatriptan succinate (Form II) was dissolved in the beaker and the pH of the resulting solution was measured. The measured pH of 5.7-5.8 indicated that the sumatriptan succinate in solution was in salt form, as opposed to free base form.

10

To confirm the stoichiometric ratio of the sumatriptan succinate (Form II), samples were prepared with a carefully measured mass of the salt dissolved in a known volume of 85:15 v/v water:acetonitrile. This sample was characterized by HPLC, and the quantity of sumatriptan was compared to that measured from samples of the Form I polymorph (1:1) prepared similarly. The quantity of sumatriptan was determined to be the same in both forms I and II. This provides further confirmation that the material is crystalline, nonsolvated 1:1 sumatriptan succinate salt (Form II).

15

A sample of sumatriptan succinate Form II was examined by PXRD, using a collection time of 10 minutes. Results of this measurement are illustrated in Figures 1, and 2(a). The PXRD pattern for sumatriptan succinate Form II has a powder X-ray diffraction pattern with peaks at 2-theta angles comprising: 5.83, 13.65, 14.56, 17.63, 18.63, 20.50, 22.35, 23.29, and 24.59 degrees. Any one or a combination of any two, any three, any four, any five, or any six or more of the peaks listed above or those in the diffractogram in Figure 1.

20

25

Comparative PXRD values for sumatriptan succinate Form I are illustrated in Figure 6 and in Example 3.

5

DSC analysis of sumatriptan succinate form II was performed by placing 0.223 mg of sample in an aluminum pan with a press fitted pan closure, and the temperature was raised from 30 degrees C to 300 degrees C. The results of these measurements are illustrated in Figure 2. Figure 2 shows the DSC traces of both sumatriptan succinate forms I and II, where form I ("Stable Form") is the top trace and form II ("New Form") is the bottom trace. Sumatriptan succinate form II demonstrated an endothermic transition at  $161 \pm 1.0$  degrees C and a larger endothermic transition at  $169 \pm 1.0$  degrees C.

15 TGA analysis of sumatriptan succinate form II was performed by placing 0.57 mg of sample in the sample pan. The starting temperature was 25 degrees C with a heating rate of 10 degrees C/minute, and the ending temperature was 300 degrees C. The results of these measurements are illustrated in Figure 3. Figure 3 shows the TGA traces of both sumatriptan succinate forms I and II, where form I ("Stable Form") is the top trace and form II ("New Form") is the bottom trace. TGA analysis confirmed that the novel sumatriptan succinate polymorph does not contain substantial amounts of either dioxane or anisole.

25 The results of Raman spectroscopic analysis of the sumatriptan succinate methanol polymorph are illustrated in Figure 4. Figure 4 shows the Raman spectra of both sumatriptan succinate forms I and II, where form I ("Stable Form") is the top spectrum and form II ("New Form") is the bottom spectrum. Several peaks in the Raman spectrum of the sumatriptan succinate form II are present in the spectrum of sumatriptan succinate form I, including 1549.8, 1352.5 and 1189.1  $\text{cm}^{-1}$ . However, many characteristics of the Raman spectrum of sumatriptan succinate Form II are not present in the sumatriptan succinate form I spectrum and include, but are not limited to: 1443.4, 1410.9, 1318.4, 1308.6, 1265.1, 1235.6, 1115.0, 991.5, 942.4, and 930.7  $\text{cm}^{-1}$ .

## 5 EXAMPLE 2

SYNTHESIS AND ANALYSIS OF SUMATRIPTAN SUCCINATE (FORM III)

An additional sumatriptan succinate polymorphic form (Form III) was prepared using a similar procedure as that described above. In order to obtain polymorphic form III of the sumatriptan succinate salt, polypropylene vials with a volume of 100 microliters were used with a normal (allowed to equilibrate at room temperature) cooling rate, and no vial treatment with a solvent or rinse. The vial was not stirred and no thermal cycling was completed. The initial sumatriptan succinate salt was dispensed in solution. It is possible to obtain form III by changing some of the parameters noted above. Table III, below, illustrates the effect of various general process parameters on the form of sumatriptan succinate that is crystallized in accordance with the instant invention.

Table III

Process Parameter	Conditions Tested	Impact on crystal form
Vial shape, combined with crystallization volume	Cylindrical, small cylinders, CMax, polypropylene Cmax: 100, 200, 500 microliters	Strong
Vial material	Glass, polypropylene	Weak
Cooling rate	Normal, quench in ice	Moderate
Vial treatment	Acetone, base rinse	Strong
Mixing rate	Stirring, no stirring	Strong
Thermal cycling	0, 1, 2 thermal cycles	Weak
Dispense method	Liquid, solid	Weak

20

In Table III, the terms “Strong”, “Moderate” and “Weak” denote general tendencies to form sumatriptan succinate forms II or III instead of form I. Smaller vial shapes and volumes drive more efficient formation of forms II and III. A rapid cooling rate drives more efficient formation of forms II or III. Similarly, treatment of the sample vial with a solvent such as acetone or a base rinse and stirring of the salt solution both drive more efficient formation of forms II or III.

25

5           Figure 5 shows a PXRD pattern of sumatriptan succinate form III. The data are shown without the background removed. Characteristic PXRD peaks of sumatriptan succinate form III include, but are not limited to, 7.31, 14.63, 17.49, 21.05, 21.71, 22.99, and 24.01 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or more of the above peaks or of those in  
10   Figure 5 can be used to characterize sumatriptan succinate form III.

### EXAMPLE 3

#### SUMATRIPTAN SUCCINATE FORM I

Sumatriptan succinate (classified herein as form I) was purchased from  
15   Quimica Sintetica SA (Madrid, Spain). The material was characterized by single-crystal x-ray analysis. Sumatriptan succinate form I was determined to be a member of the P21/c space group and exhibit the following single-crystal x-ray parameters:  $a = 9.8852$  angstroms,  $b = 11.2255$  angstroms,  $c = 18.649$  angstroms,  $\alpha = 90$  degrees,  $\beta = 92.796$  degrees,  $\gamma = 90$  degrees.

20

Figure 6 shows a PXRD pattern derived from the single-crystal x-ray analysis (top) and experimental PXRD data acquired of sumatriptan succinate form I (bottom). The experimental PXRD diffractogram of sumatriptan succinate form I acquired comprises peaks at 9.14, 12.65, 13.31, 15.44, 15.74, 16.42, 19.93, 20.62,  
25   21.38, 22.10, 22.77, and 26.96 degrees 2-theta. Any small peak shifts between the above patterns may be due to a colder temperature during single-crystal data acquisition. Figures 7A-C are packing diagrams of sumatriptan succinate form I.

## 5 EXAMPLE 4

SUMATRIPTAN SUCCINATE DICHLOROMETHANE HEMISOLVATE

400 microliters of sumatriptan succinate solution (20 mg/mL in 90:10 v/v water:methanol) was added to a cylindrical glass vial with a multipipettor. The solvent was evaporated to leave a transparent film in the vial bottom. 400 microliters  
10 of dichloromethane was added. The samples were capped and placed on a temperature-controlled hotstage at 50 degrees C for 20 minutes, then allowed to cool to room temperature overnight. Solids were isolated by removing the solvent with a pipet, and allowed to air dry.

15 Figure 8 shows a PXRD pattern of the dichloromethane hemisolvate of sumatriptan succinate. Characteristic PXRD peaks of sumatriptan succinate dichloromethane hemisolvate include, but are not limited to, 12.57, 13.77, 15.52, 16.79, 17.64, 19.07, 19.92, 22.06, 22.78, 23.49, 28.66, and 29.82 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or  
20 more of the above peaks or of those in Figure 8 can be used to characterize sumatriptan succinate dichloromethane hemisolvate.

DSC analysis was performed on the dichloromethane hemisolvate and the thermogram is depicted in Figure 9. In Figure 9, the top DSC trace is of the  
25 dichloromethane hemisolvate of sumatriptan succinate and the bottom trace is of sumatriptan succinate form I. The hemisolvate shows an endothermic transition near 166.7 degrees C.

TGA analysis was performed on the dichloromethane hemisolvate and the  
30 thermogram is depicted in Figure 10. In Figure 10, an approximate 9 percent weight loss is measured between room temperature and 125 degrees C.

Single-crystal data analysis was also completed on the dichloromethane hemisolvate of sumatriptan succinate. The space group was determined to be P21/c  
35 and the single-crystal parameters were as follows: a = 10.0095 angstroms, b =

- 5     12.4315 angstroms,  $c = 17.1489$  angstroms,  $\alpha = 90$  degrees,  $\beta = 91.478$  degrees,  $\gamma = 90$  degrees.

#### EXAMPLE 5

##### SOLVATES OF SUMATRIPTAN SUCCINATE

- 10             Several solvates were made by adding specified volumes of sumatriptan succinate solution (20 mg/mL in 90:10 v/v water:methanol) to a cylindrical glass vial with a multipipettor. The solvent was evaporated to leave a transparent film in the vial bottom. The specified volume of crystallization solvent was added (500 microliters isobutanol, 50 microliters 1,4-dioxane, 50 microliters tetrahydrofuran, 500  
15     microliters 1,2-dichloroethane), samples were capped and placed on a temperature-controlled hotstage at 50 degrees C for 20 minutes, then allowed to cool to room temperature overnight. Solids were isolated by removing a solvent with a pipet, and allowed to air dry.

- 20             An isobutanol solvate of sumatriptan succinate was prepared by the above method. PXRD analysis was completed and is found in Figure 11. PXRD peaks of the isobutanol solvate include, but are not limited to, 7.11, 14.27, 16.41, 17.25, 18.75, 21.89, and 23.19 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or more of the above peaks or of those in Figure 11 can  
25     be used to characterize sumatriptan succinate isobutanol solvate.

- A 1,4-dioxane solvate of sumatriptan succinate was prepared by the above method. PXRD analysis was completed and is found in Figure 12. The data are shown without the background removed. PXRD peaks of the 1,4-dioxane solvate include,  
30     but are not limited to, 5.59, 8.79, 13.47, 14.67, 17.51, 19.49, 21.17 and 23.75 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or more of the above peaks or of those in Figure 12 can be used to characterize sumatriptan succinate 1,4-dioxane solvate.

- 35             A tetrahydrofuran solvate of sumatriptan succinate was prepared by the above method. PXRD analysis was completed and is found in Figure 13. The data are shown

5 without the background removed. PXRD peaks of the tetrahydrofuran solvate include, but are not limited to, 5.73, 8.87, 13.47, 14.67, 17.47, 18.67, 19.57 and 21.21 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or more of the above peaks or of those in Figure 13 can be used to characterize sumatriptan succinate tetrahydrofuran solvate.

10

A 1,2-dichloroethane solvate of sumatriptan succinate was prepared by the above method. PXRD analysis was completed and is found in Figure 14. The data are shown without the background removed. PXRD peaks of the 1,2-dichloroethane solvate include, but are not limited to, 5.85, 13.65, 14.61, 17.65, 18.57, 19.57, 20.56, 15 and 22.41 degrees 2-theta. Any one, or any combination of any two, any three, any four, any five, or any six or more of the above peaks or of those in Figure 14 can be used to characterize sumatriptan succinate 1,2-dichloroethane solvate.

5

What is claimed is:

1. A soluble crystalline form of sumatriptan comprising:
  - (a) a salt comprising the reaction product of sumatriptan and an organic acid or an  
10 inorganic acid;
  - (b) a solvate of sumatriptan or a solvate of a salt of sumatriptan; or
  - (c) a polymorph of sumatriptan or a polymorph of a salt of sumatriptan.
2. The soluble crystalline form of sumatriptan of claim 1, wherein the soluble  
15 crystalline form comprises sumatriptan succinate.
3. The soluble crystalline form of sumatriptan of claim 1, comprising the reaction product of sumatriptan and an organic or inorganic acid.
- 20 4. The soluble crystalline form of sumatriptan of claim 1, wherein the soluble crystalline form of sumatriptan is a hydrate.
5. The soluble crystalline form of sumatriptan of claim 1, wherein the soluble crystalline form is an organic solvate of a sumatriptan salt formed by the reaction of  
25 sumatriptan and an organic or inorganic acid.
6. The soluble crystalline form of sumatriptan of claim 5, wherein the sumatriptan salt is sumatriptan succinate.
- 30 7. The soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is an alcohol solvate.
8. The soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is a dichloromethane hemisolvate.

35

5 9. The soluble crystalline form of sumatriptan of claim 8, wherein the hemisolvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- 10 (a) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises peaks at 12.57 and 15.52 degrees;
- (b) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises peaks at 13.77, 19.07, and 22.06 degrees;
- 15 (c) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises peaks at 17.63 and 22.78 degrees;
- (d) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises a peak at 12.57 degrees;
- 20 (e) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises peaks at 16.79, 19.92, and 23.49 degrees; or
- (f) said form is sumatriptan succinate dichloromethane hemisolvate and said X-ray diffraction pattern comprises peaks at 13.77 and 25 16.79 degrees.

10. The soluble crystalline form of sumatriptan of claim 8, wherein the hemisolvate is characterized by thermal analysis, wherein:

- 30 (a) said form is sumatriptan succinate dichloromethane hemisolvate and said thermal analysis comprises a DSC thermogram with an endothermic transition at about 167 degrees C; or
- (b) said form is sumatriptan succinate dichloromethane hemisolvate and said thermal analysis comprises a TGA thermogram with an approximate 9 percent weight loss between about room 35 temperature and 125 degrees C.

5 11. The soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is an isobutanol solvate.

12. The soluble crystalline form of sumatriptan of claim 11, wherein the solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in  
10 terms of 2-theta angles, wherein:

- (a) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises peaks at 7.11 and 21.89 degrees;
- (b) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises peaks at 14.27 and 18.75 degrees;
- 15 (c) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises peaks at 7.11, 14.27, and 23.19 degrees;
- (d) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises a peak at 7.11 degrees;
- 20 (e) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises peaks at 14.27, 16.41, and 17.25 degrees; or
- (f) said form is sumatriptan succinate isobutanol solvate and said X-ray diffraction pattern comprises peaks at 17.25 and 21.89 degrees.

25

13. A soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is an 1,4-dioxane solvate.

14. The soluble crystalline form of sumatriptan of claim 13, wherein the solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in  
30 terms of 2-theta angles, wherein:

- (a) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises peaks at 13.47, 17.51, and 21.17 degrees;
- 35 (b) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises peaks at 5.59 and 13.47 degrees;

- 5 (c) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises peaks at 8.79 and 17.51 degrees;
- (d) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises a peak at 13.47 degrees;
- 10 (e) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises peaks at 14.67, 19.49 and 21.17 degrees; or
- (f) said form is sumatriptan succinate 1,4-dioxane solvate and said X-ray diffraction pattern comprises peaks at 13.47 and 17.51 degrees.

15 15. A soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is a tetrahydrofuran solvate.

16. The soluble crystalline form of sumatriptan of claim 15, wherein the solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- 20 (a) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises peaks at 5.73, 13.47, and 17.47 degrees;
- 25 (b) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises peaks at 8.87 and 14.67 degrees;
- (c) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises peaks at 13.47, 17.47, and 21.21 degrees;
- 30 (d) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises a peak at 5.73 degrees;
- (e) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises peaks at 17.47 and 19.57 degrees; or

- 5 (f) said form is sumatriptan succinate tetrahydrofuran solvate and said X-ray diffraction pattern comprises peaks at 5.73 and 17.47 degrees.

10 17. A soluble crystalline form of sumatriptan of claim 6, wherein the organic solvate is a 1,2-dichloroethane solvate.

18. The soluble crystalline form of sumatriptan of claim 17, wherein the solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- 15 (a) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises peaks at 5.85 and 17.65 degrees;
- (b) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises peaks at 13.65, 17.65, and 18.57 degrees;
- 20 (c) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises peaks at 5.85, 13.65, and 20.56 degrees;
- (d) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises a peak at 13.65 degrees;
- 25 (e) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises peaks at 14.61 and 17.65 degrees; or
- (f) said form is sumatriptan succinate 1,2-dichloroethane solvate and said X-ray diffraction pattern comprises peaks at 14.61 and 22.41 degrees.
- 30

19. A soluble crystalline form of sumatriptan of claim 1, where the soluble crystalline form comprises a form selected from the group consisting of sumatriptan succinate, sumatriptan tartrate, sumatriptan citrate, sumatriptan fumarate, sumatriptan malonate,

35

5 sumatriptan maleate, sumatriptan adipate, sumatriptan di-mesylate, sumatriptan sulfate, sumatriptan benzenesulfonate, and sumatriptan phosphate.

20. A soluble crystalline form of sumatriptan of claim 1, where the soluble crystalline form is a co-crystal.

10

21. A soluble crystalline form of sumatriptan comprising form II or form III of sumatriptan succinate.

15

22. The soluble crystalline form of sumatriptan of claim 21, wherein the form is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

(a) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises peaks at 5.83 and 13.65 degrees;

20

(b) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises peaks at 14.56, 17.63, and 22.35 degrees;

(c) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises peaks at 13.65 and 17.63 degrees;

25

(d) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises a peak at 5.83 degrees;

(e) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises peaks at 14.56 and 18.63 degrees;

(f) said form is sumatriptan succinate form II and said X-ray diffraction pattern comprises peaks at 5.83 and 17.63 degrees;

30

(g) said form is sumatriptan succinate form III and said X-ray diffraction pattern comprises peaks at 7.31 and 14.63 degrees;

(h) said form is sumatriptan succinate form III and said X-ray diffraction pattern comprises peaks at 17.49 and 21.05 degrees;

35

(i) said form is sumatriptan succinate form III and said X-ray diffraction pattern comprises peaks at 7.31, 17.49, and 21.05 degrees;

- 5 (j) said form is sumatriptan succinate form III and said X-ray diffraction pattern comprises peaks at 14.63 and 18.15 degrees; or  
(k) said form is sumatriptan succinate form III and said X-ray diffraction pattern comprises a peak at 7.31 degrees.

10 23. The soluble crystalline form of sumatriptan of claim 21, wherein the form is characterized by a Raman spectrum or a DSC thermogram, wherein:

- (a) said form is sumatriptan succinate form II and said Raman spectrum comprises peaks at 1443 and 1264  $\text{cm}^{-1}$ ;  
(b) said form is sumatriptan succinate form II and said Raman spectrum  
15 comprises peaks at 1318, 1265, and 992  $\text{cm}^{-1}$ ;  
(c) said form is sumatriptan succinate form II and said Raman spectrum comprises peaks at 1411 and 1236  $\text{cm}^{-1}$ ;  
(d) said form is sumatriptan succinate form II and said Raman spectrum comprises a peak at 1265  $\text{cm}^{-1}$ ;  
20 (e) said form is sumatriptan succinate form II and said Raman spectrum comprises peaks at 1115 and 992  $\text{cm}^{-1}$ ; or  
(f) said form is sumatriptan succinate form II and said DSC thermogram comprises an endothermic transition at about 161 degrees C.

25 24. The soluble crystalline form of sumatriptan of claim 21, further comprising an organic solvate.

25. The soluble crystalline form of sumatriptan of claim 24, wherein the organic solvate is an alcohol solvate.

30

26. The soluble crystalline form of sumatriptan of claim 225, wherein the alcohol is methanol, ethanol, propanol, butanol, or isobutanol.

27. A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier  
35 and a therapeutically effective amount of a compound of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26.

5

28. The pharmaceutical dosage form of claim 27, wherein the dosage form may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

10

29. The pharmaceutical dosage form of claim 27, wherein the dosage form is a prodrug or a controlled release dosage form.

30. The pharmaceutical dosage form of claim 27, wherein the dosage form comprises at least one pharmaceutically acceptable excipient or diluent is an antioxidant.

15

31. A method of treating a migraine or related neurological disorder, comprising administering to a mammal suffering from one or more of such disorders a therapeutically effective amount of a pharmaceutical dosage form of claim 30.

20

32. The method of claim 31, wherein the mammal is a human.

33. A method of preventing a migraine or related neurological disorder, comprising administering to a mammal a prophylactically effective amount of a pharmaceutical dosage form of claim 27.

25

34. The method of claim 31, wherein

(a) the therapeutically or prophylactically effective amount is from about 10 mg to about 1000 mg per day; or

30

(b) the dosage form is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

35. The method of claim 33, wherein

(a) the therapeutically or prophylactically effective amount is from about 10 mg to about 1000 mg per day; or

35

(b) the dosage form is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.

5

36. A method of altering the crystal form of a soluble crystalline form of sumatriptan by changing a parameter selected from the group consisting of vial shape/size, vial material, cooling rate, vial treatment, mixing rate, thermal cycling, and dispense method.

10

37. The method of altering the crystal form of a soluble crystalline form of sumatriptan of claim 36, wherein the vial shape/size is decreased.

15

38. The method of altering the crystal form of a soluble crystalline form of sumatriptan of claim 36, wherein the cooling rate is increased.

39. The method of altering the crystal form of a soluble crystalline form of sumatriptan of claim 36, wherein the vial is treated with a solvent or a solution.

20

40. The method of altering the crystal form of a soluble crystalline form of sumatriptan of claim 39, wherein the vial is treated with acetone or a base rinse.

41. The method of altering the crystal form of a soluble crystalline form of sumatriptan of claim 36, wherein the mixing rate is increased by stirring.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 7C




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/005560

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 7 C07C303/40 C07C303/44 C07D209/14 C07C311/35		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03/105836 A (RAJAN SRINIVASAN THIRUMALAI ; REDDY MANNE SATYANARAYANA (IN); MURTHY M) 24 December 2003 (2003-12-24) the whole document	1-41
P, X	US 2003/181432 A1 (LANCASTER ET AL.) 25 September 2003 (2003-09-25) *abstract; paragraph 28 and the claims*	1-41
X	EP 0 490 689 A (GLAXO GROUP LTD) 17 June 1992 (1992-06-17) the whole document	1-41
X	EP 0 503 440 A (GLAXO GROUP LTD) 16 September 1992 (1992-09-16) *abstract; page 2; page 3, lines 1 and 2; the examples and the claims*	1-41
--/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "C" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  30 July 2004		Date of mailing of the international search report  06/08/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Lorenzo Varela, M.J.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/005560

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 037 845 A (OXFORD ALEXANDER W) 6 August 1991 (1991-08-06) *examples 3-20 and the claims* -----	1-41
X	US 6 255 502 B1 (PENKLER LAWRENCE JOHN ET AL) 3 July 2001 (2001-07-03) *examples 1, 8, 9-11, 14, 16 and 17; tables 1 and 2 and the claims* -----	1-41
X	GB 2 162 522 A (GLAXO GROUP LTD) 5 February 1986 (1986-02-05) *page 1; examples 8, 16-20 and the claims* -----	1-41
X	US 4 816 470 A (COATES IAN H ET AL) 28 March 1989 (1989-03-28) the whole document -----	1-41

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/005560

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 31-35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/005560

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03105836	A	24-12-2003	WO 03105836 A1	24-12-2003
US 2003181432	A1	25-09-2003	AU 6621801 A	08-01-2002
			EP 1294359 A1	26-03-2003
			WO 0200198 A1	03-01-2002
			JP 2004500983 T	15-01-2004
EP 0490689	A	17-06-1992	AP 230 A	27-01-1993
			AT 119881 T	15-04-1995
			AU 650706 B2	30-06-1994
			AU 9072091 A	08-07-1992
			BE 1005085 A3	13-04-1993
			CA 2098302 A1	13-06-1992
			CH 684192 A5	29-07-1994
			CN 1063099 A ,B	29-07-1992
			CN 1128259 A ,B	07-08-1996
			CZ 9301140 A3	16-02-1994
			CY 2005 A	05-12-1997
			DE 69108200 D1	20-04-1995
			DE 69108200 T2	20-07-1995
			DK 490689 T3	22-05-1995
			EG 20219 A	30-11-1997
			WO 9210477 A1	25-06-1992
			EP 0490689 A1	17-06-1992
			ES 2069836 T3	16-05-1995
			FR 2670487 A1	19-06-1992
			GB 2251614 A ,B	15-07-1992
			GR 3015430 T3	30-06-1995
			HK 82697 A	27-06-1997
			HU 9500422 A3	28-09-1995
			IE 914317 A1	17-06-1992
			IL 100330 A	18-06-1996
			IT 1252868 B	28-06-1995
			JP 2994037 B2	27-12-1999
			JP 6503560 T	21-04-1994
			KR 211479 B1	02-08-1999
			MX 9102501 A1	01-09-1992
			NL 9102071 A	01-07-1992
			NZ 240942 A	25-03-1994
			PT 99757 A ,B	31-12-1992
			RU 2108328 C1	10-04-1998
			US 5554639 A	10-09-1996
			US 5705520 A	06-01-1998
			ZA 9109750 A	28-10-1992
EP 0503440	A	16-09-1992	AT 165973 T	15-05-1998
			AU 663303 B2	05-10-1995
			AU 1326492 A	06-10-1992
			BE 1005086 A5	13-04-1993
			CA 2105180 A1	09-09-1992
			CH 684242 A5	15-08-1994
			CZ 9301849 A3	15-06-1994
			CY 2011 A	20-02-1998
			DE 69225421 D1	18-06-1998
			DE 69225421 T2	15-10-1998
			DK 503440 T3	18-01-1999
			WO 9215295 A1	17-09-1992
			EP 0503440 A1	16-09-1992

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/005560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0503440	A	ES 2117015 T3	01-08-1998
		FR 2673538 A1	11-09-1992
		GB 2254784 A ,B	21-10-1992
		HK 19395 A	17-02-1995
		IE 920726 A1	09-09-1992
		IL 101162 A	20-11-1997
		IT 1271495 B	30-05-1997
		JP 2986546 B2	06-12-1999
		JP 6505020 T	09-06-1994
		KR 202042 B1	15-06-1999
		MX 9200992 A1	01-09-1992
		NL 9200423 A	01-10-1992
		NZ 241873 A	27-06-1994
		OA 9812 A	15-04-1994
		RU 2098093 C1	10-12-1997
		SG 169294 G	28-04-1995
		US 2002197318 A1	26-12-2002
		US 6020001 A	01-02-2000
		US 5863559 A	26-01-1999
		US 6368627 B1	09-04-2002
		ZA 9201690 A	02-08-1993
US 5037845	A	06-08-1991	
		AT 386196 B	11-07-1988
		AT 226685 A	15-12-1987
		AU 573878 B2	23-06-1988
		AU 4568985 A	06-02-1986
		BE 903006 A1	03-02-1986
		CA 1241004 A1	23-08-1988
		CH 666026 A5	30-06-1988
		CZ 9104041 A3	14-04-1993
		CY 1475 A	21-07-1989
		DE 3527648 A1	13-02-1986
		DK 351185 A ,B,	02-02-1986
		EG 17283 A	30-06-1992
		ES 8700234 A1	01-01-1987
		ES 8801204 A1	01-03-1988
		ES 8801788 A1	01-05-1988
		ES 8801789 A1	01-05-1988
		ES 8801900 A1	16-05-1988
		ES 8801790 A1	01-05-1988
		FI 852969 A ,B,	02-02-1986
		FR 2568571 A1	07-02-1986
		GB 2162522 A ,B	05-02-1986
		GR 851850 A1	26-11-1985
		HK 33289 A	28-04-1989
		HU 40077 A2	28-11-1986
		IE 58122 B1	14-07-1993
		IL 75986 A	28-02-1989
		IT 1207325 B	17-05-1989
		JP 1894608 C	26-12-1994
		JP 6023197 B	30-03-1994
		JP 61047464 A	07-03-1986
		KE 3858 A	02-06-1989
		KR 9303759 B1	10-05-1993
		LU 86032 A1	18-02-1986
		LU 88266 A9	03-02-1994
		MA 20499 A1	01-04-1986
		MX 159672 A	02-08-1989

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/005560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5037845	A	MX 14221 A	01-10-1993
		NL 930065 I1	01-09-1993
		NL 8502171 A ,C	03-03-1986
		NO 853046 A ,B,	03-02-1986
		NZ 212948 A	29-05-1989
		PH 22850 A	19-01-1989
		PH 24117 A	05-03-1990
		PL 254800 A1	21-10-1986
		PT 80900 B	30-12-1987
		PT 80900 A	01-09-1985
		SE 452460 B	30-11-1987
		SE 8503680 A	02-02-1986
		SK 404191 A3	13-09-1995
		SU 1498386 A3	30-07-1989
US 6255502	B1	03-07-2001	
		AU 3455297 A	09-02-1998
		BR 9710289 A	17-08-1999
		EP 1024833 A1	09-08-2000
		JP 2001508027 T	19-06-2001
		AU 712546 B2	11-11-1999
		AU 3455197 A	09-02-1998
		BR 9710241 A	10-08-1999
		CA 2257860 A1	22-01-1998
		CA 2259418 A1	22-01-1998
		CN 1230123 A	29-09-1999
		WO 9802186 A1	22-01-1998
		WO 9802187 A1	22-01-1998
		JP 2000505090 T	25-04-2000
		KR 2000022239 A	25-04-2000
		KR 2000023708 A	25-04-2000
		ZA 9706178 A	03-02-1998
		ZA 9706179 A	03-02-1998
GB 2162522	A	05-02-1986	
		CY 1475 A	21-07-1989
		AT 386196 B	11-07-1988
		AT 226685 A	15-12-1987
		AU 573878 B2	23-06-1988
		AU 4568985 A	06-02-1986
		BE 903006 A1	03-02-1986
		CA 1241004 A1	23-08-1988
		CH 666026 A5	30-06-1988
		CZ 9104041 A3	14-04-1993
		DE 3527648 A1	13-02-1986
		DK 351185 A ,B,	02-02-1986
		EG 17283 A	30-06-1992
		ES 8700234 A1	01-01-1987
		ES 8801204 A1	01-03-1988
		ES 8801788 A1	01-05-1988
		ES 8801789 A1	01-05-1988
		ES 8801900 A1	16-05-1988
		ES 8801790 A1	01-05-1988
		FI 852969 A ,B,	02-02-1986
		FR 2568571 A1	07-02-1986
		GR 851850 A1	26-11-1985
		HK 33289 A	28-04-1989
		HU 40077 A2	28-11-1986
		IE 58122 B1	14-07-1993
		IL 75986 A	28-02-1989

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/005560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2162522	A	IT 1207325 B	17-05-1989
		JP 1894608 C	26-12-1994
		JP 6023197 B	30-03-1994
		JP 61047464 A	07-03-1986
		KE 3858 A	02-06-1989
		KR 9303759 B1	10-05-1993
		LU 86032 A1	18-02-1986
		LU 88266 A9	03-02-1994
		MA 20499 A1	01-04-1986
		MX 159672 A	02-08-1989
		MX 14221 A	01-10-1993
		NL 930065 I1	01-09-1993
		NL 8502171 A ,C	03-03-1986
		NO 853046 A ,B,	03-02-1986
		NZ 212948 A	29-05-1989
		PH 22850 A	19-01-1989
		PH 24117 A	05-03-1990
		PL 254800 A1	21-10-1986
		PT 80900 B	30-12-1987
		PT 80900 A	01-09-1985
		SE 452460 B	30-11-1987
		SE 8503680 A	02-02-1986
		SK 404191 A3	13-09-1995
		SU 1498386 A3	30-07-1989
		US 5037845 A	06-08-1991
US 4816470	A	28-03-1989	
		AT 381933 B	10-12-1986
		AT 208483 A	15-05-1986
		AU 566149 B2	08-10-1987
		AU 1544183 A	15-12-1983
		BE 896986 A1	07-12-1983
		CA 1199643 A1	21-01-1986
		CH 657359 A5	29-08-1986
		CZ 9104040 A3	14-04-1993
		CY 1458 A	21-07-1989
		DE 3320521 A1	08-12-1983
		ES 8407473 A1	16-12-1984
		ES 8601880 A1	01-03-1986
		ES 8609247 A1	16-12-1986
		FI 832035 A ,B,	08-12-1983
		FR 2530625 A1	27-01-1984
		GB 2124210 A ,B	15-02-1984
		GR 79215 A1	22-10-1984
		HK 14789 A	24-02-1989
		IE 55358 B1	29-08-1990
		IL 68913 A	31-08-1987
		IT 1170387 B	03-06-1987
		JP 1664600 C	19-05-1992
		JP 3029069 B	23-04-1991
		JP 59042366 A	08-03-1984
		KE 3833 A	18-11-1988
		KR 9006681 B1	17-09-1990
		LU 84852 A1	29-03-1985
		MX 9202623 A1	30-06-1992
		MY 17987 A	31-12-1987
		NL 8302031 A ,B,	02-01-1984
		NZ 204482 A	10-09-1986
		PH 19908 A	13-08-1986

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/005560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4816470	A	PT 76830 A ,B	01-07-1983
		SE 452459 B	30-11-1987
		SE 8303208 A	08-12-1983
		SK 404091 A3	07-06-1995
		ZA 8304110 A	30-01-1985
<hr/>			